XNAS
PGNY
Market cap2.19bUSD
Oct 08, Last price
27.83USD
1D
1.02%
1Q
-9.20%
IPO
61.71%
Name
Progyny Inc
Chart & performance
P/E
37.25
P/S
1.69
EPS
0.75
Div yield, %
—
Shrs. gr., 5y
-2.02%
Rev. gr., 5y
30.17%
Revenues
1.29b
+10.40%
Net income
59m
+7.70%
CFO
210m
+17.36%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Progyny, Inc. functions as a benefits management corporation, dedicated to providing specialized solutions for fertility and broader family-building initiatives to employers throughout the United States. Its core fertility offering is characterized by a distinctive benefits plan architecture, paired with personalized, white-glove member support services and access to a meticulously chosen network of top-tier fertility specialists. Additionally, the company presents Progyny Rx, an all-encompassing pharmacy benefits solution that ensures its members can readily acquire the essential medications for their treatments. Moreover, Progyny facilitates employer-sponsored reimbursement programs to support surrogacy and adoption journeys. The company, which was established in 2008 and has its main offices in New York City, previously operated as Auxogyn, Inc. before adopting the Progyny, Inc. moniker in 2015.
Key people
David Schlanger
Executive Chairman of the Board · since 2022
Mark Livingston
Chief Financial Officer · since 2020
Melissa Cummings
Chief Operating Officer · since 2025
Geoffrey Clapp
Chief Product Officer · since 2025
Allison Swartz
Executive Vice President, General Counsel, Secretary · since 2022
Peter Anevski
Chief Executive Officer, Director · since 2022
Independent Director · since 2022
Kevin Gordon
Independent Director · since 2019
Roger Holstein
Independent Director · since 2020
Independent Director · since 2025
Lead Independent Director · since 2024
Norman Payson
Independent Director · since 2016
Cheryl Scott
Independent Director · since 2019
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||